Search Results

You are looking at 1 - 10 of 33 items for :

  • "angiogenesis inhibitor" x
Clear All
Full access

Erica L. Mayer, Nancy U. Lin and Harold J. Burstein

New biological therapies continue to emerge in breast cancer. Recent advances with anti-angiogenesis therapies and anti-HER2 therapies highlight the next generation of treatments that will be entering clinical practice. Important questions regarding these targeted treatments remain, however. There are uncertainties as to how best to integrate new drugs into existing treatment algorithms, whether to use monotherapy or combination therapy with chemotherapy, and how to manage novel side effects seen with these agents. This review highlights recent advances with the anti-vascular endothelial growth factor antibody, bevacizumab, and the dual-kinase inhibitor, lapatinib, in the treatment of metastatic breast cancer.

Full access

: Washington University School of Medicine There has been limited benefit with angiogenesis inhibitor drugs in patients with non–small cell lung cancer (NSCLC). This study proposes that patients who are molecularly selected for treatment based on the presence

Full access

Investigator: Ramaswamy Govindan, MD Condition: Non–small cell lung cancer Institution: Washington University School of Medicine There has been limited benefit with angiogenesis inhibitor drugs in patients with non–small cell lung cancer (NSCLC). We

Full access

Investigator: Ramaswamy Govindan, MD Condition: Non–small cell lung cancer Institution: Washington University School of Medicine There has been limited benefit with angiogenesis inhibitor drugs when used with molecularly selected patients in non

Full access

James Brugarolas

therapies, including immunotherapies (interleukin-2 and nivolumab) and molecularly targeted therapies, which comprise angiogenesis inhibitors (bevacizumab, sunitinib, sorafenib, pazopanib, axitinib, and, with a characteristic target spectrum, the recently

Full access

investigational and not approved by the U.S. Food and Drug Administration (FDA). Its safety and efficacy have not been established. 2 Angiogenesis inhibitors. NCI Web site. Available at: http://www.cancer.gov/cancertopics/factsheet/Therapy/angiogenesis-inhibitors

Full access

Gary R. Hudes, Michael A. Carducci, Toni K. Choueiri, Peg Esper, Eric Jonasch, Rashmi Kumar, Kim A. Margolin, M. Dror Michaelson, Robert J. Motzer, Roberto Pili, Susan Roethke and Sandy Srinivas

bevacizumab varies with tumor type, with a higher risk seen in patients with RCC (RR, 5.14; 95% CI, 1.35–19.64) than in controls not receiving bevacizumab. 112 ATE may be a class effect of angiogenesis inhibitors. Treatment with the VEGFR inhibitors sunitinib

Full access

Philip J. Saylor and M. Dror Michaelson

Davis ID Machiels JP . Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor [abstract] . J Clin Oncol 2008 ; 26 ( Suppl 1 ): Abstract 5046

Full access

Andrew H. Ko and Margaret A. Tempero

a poor prognosis for patients with ductal pancreatic adenocarcinoma . Cancer 2000 ; 88 : 2239 – 2245 . 54 Hotz HG Reber HA Hotz B . Angiogenesis inhibitor TNP-470 reduces human pancreatic cancer growth . J Gastrointest Surg 2001 ; 5

Full access

Deborah K. Armstrong

been as effective, she added. Future Agents A number of experimental agents are exciting, including the angiogenesis inhibitor AMG-386; farletuzumab, a monoclonal antibody targeting folate receptor-alpha; and poly(ADP-ribose) polymerase (PARP